Another specific CAR T-cell BCMA (B cell maturation antigen)-CD24 CAR-T, a novel multiple myeloma immunotherapy, was developed by Fumou Sun et al. They have demonstrated strong cytotoxic activity and selectivity for multiple myeloma cells in vitro and in vivo (293). The gene discussed is CD24; the disease is plasma cell myeloma.